z-logo
Premium
Low doses of recombinant human erythropoietin does not affect C‐terminal FGF23 in healthy men
Author(s) -
Bejder Jacob,
Robach Paul,
Lundby AnneKristine,
Cornu Catherine,
Sallet Pierre,
Cairo Gaetano,
Lundby Carsten
Publication year - 2020
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.2795
Subject(s) - erythropoietin , placebo , medicine , saline , subcutaneous injection , dose , endocrinology , recombinant dna , urology , chemistry , pathology , biochemistry , alternative medicine , gene
Recombinant human erythropoietin (rhEpo) can improve human performance, but misuse remains difficult to detect. C‐terminal fibroblast growth factor 23 (cFGF23) was recently demonstrated to increase following injection of a single high dose rhEpo, but the effect of more frequent low doses is unknown. Using a randomized double‐blind placebo‐controlled design, we investigated whether 2 weeks of subcutaneous injections three times a week of 50 IU/kg Eprex (low‐dose) or 20 IU/kg Eprex (micro‐dose) increase cFGF23 levels compared with saline (placebo) injections in 24 healthy males. Venous blood was sampled at day −3, 0, 1, 3, 11, 14, 18, and 25 of the treatment and analyzed for cFGF23 and erythropoietin concentration ([EPO]). The level of cFGF23 was similar at days −3, 0, 1, 3, 11, 14, 18, and 25 with the low‐dose (23 ± 4, 26 ± 5, 23 ± 7, 27 ± 6, 25 ± 8, 24 ± 10, 22 ± 5, and 24 ± 7 RU/mL, respectively), micro‐dose (23 ± 6, 25 ± 5, 23 ± 8, 28 ± 9, 27 ± 7, 25 ± 9, 25 ± 5, and 23 ± 6 RU/mL, respectively) and placebo (23 ± 6, 24 ± 6, 26 ± 7, 26 ± 6, 31 ± 6, 31 ± 7, 24 ± 4, and 27 ± 8 RU/mL, respectively) treatment. The correlation coefficient between plasma [EPO] and plasma cFGF23 levels was R 2 = 0.01 and insignificant. The results demonstrate that cFGF23 is not sensitive to low doses of subcutaneous rhEpo injections in healthy males.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here